In a phase 2 trial, patients having an urticaria exacerbation who used the spray report better hive and pruritus scores than ...

Enrollment completed six months ahead of guidance, driven by significant unmet need for better treatments in CSUTopline data ...

Outside the drug’s current urticaria niche, Novartis is also developing remibrutinib in myasthenia gravis and multiple ...

Patients with chronic spontaneous urticaria and positive CU Index results or a combination of low IgE and low blood histamine ...

Omalizumab shows superior efficacy to dupilumab in reducing symptoms in patients with chronic spontaneous urticaria.

Medically reviewed by Katlein Franca, MD Doctors use a process of elimination to diagnose chronic hives, rather than a single ...

Remibrutinib shows significant complete response rates across 3 chronic inducible urticaria subtypes in the phase 3 RemIND trial.

The postpartum period is a time for recovery and healing. When you are busy juggling healing, establishing breastfeeding, and adjusting to an identity shift, your skin may begin to show external ...

Analyses from REMIX-1 & -2 studies on CSU disease control and early symptom relief will be presented Phase II data evaluating safety and efficacy results of remibrutinib for treatment of peanut ...

Analyses from REMIX-1 & -2 studies on CSU disease control and early symptom relief will be presented Phase II data evaluating safety and efficacy results of remibrutinib for treatment of peanut allerg ...

In a healthy body, mast cells (the “lookout” cells of the immune system) only release histamine when they detect a foreign invader, like pollen or venom. In CSU, these cells dump histamine into the ...

Novartis reports positive topline results from pivotal phase III RemIND trial of oral remibrutinib in chronic inducible urticaria: Basel Thursday, February 19, 2026, 13:00 Hrs [IS ...